Abstracts tagged "Regulatory cells"

Abstract Number: 142 • 2018 ACR/ARHP Annual Meeting
Peripheral CD4+CD25+Foxp3+T Regulatory Cells Absolutely Reduce in Patients with Systemic Lupus Erythematosus
Xiao-Qing Liu¹, Na-Lin Lai², Yanan Duan¹, Junwei Chen¹, Xiao-Feng Li³ and Chong Gao⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Regulatory T (Treg) cells, with the capacity to suppress immune responses, and effector T (Teff) cells, to promote inflammation, have been intensively studied in…
Abstract Number: 844 • 2018 ACR/ARHP Annual Meeting
Differential Roles of Tnfα-TNFR1 and Tnfα-TNFR2 in the Differentiation and Function of Induced CD4+Foxp3+ Treg Cells in Autoimmune Diseases
SONGGUO ZHENG¹, Su-juan Yang², Julie Wang¹ and Rayford June¹, ¹Medicine, Milton S. Hershey Medical School at Penn State University, HERSHEY, PA, ²Medicine, The Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China
Background/Purpose: Tumor Necrosis Factor (TNF) α exerts it pro-inflammatory or anti-inflammatory function. This study hypothesizes that TNFα has multi-function through binding the different receptor 1…
Abstract Number: 1937 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
Ming Yan¹, Sheng-Xiao Zhang², Ruihuan Jia², Yu-Fei Hao¹, He-Hua Sun¹, Yan-Yan Wang¹, Guang-Ying Liu¹, Cai-Hong Wang³, Chong Gao⁴ and Xiao-Feng Li³, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China, ³The Second Hospital of Shanxi Medical Univerity, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) have lymphocyte dysfunction characterized by deficiency or dysfunction of regulatory T cells (Tregs), which plays crucial roles in immune tolerance. Low dose IL-2…
Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
Jia Wang¹, Sheng-Xiao Zhang², Fang-Yuan Hu³, Xiao-Juan Zheng¹, Ting Cheng¹, Na-Na Yu², Wen-Xian Yang¹, Chong Gao⁴, Hong-Yan Wen² and Xiao-Feng Li⁵, ¹Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²The Second Hospital of Shanxi Medical University, Taiyuan, China, ³Rheumatology, The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁵The Second Hospital of Shanxi Medical Univerity, Taiyuan, China
Background/Purpose: Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…
Abstract Number: 71 • 2017 ACR/ARHP Annual Meeting
The Critical Role of Interleukin-33 in Promoting Angiogenesis and Regulates Inflammation through Mast Cells in Takayasu Arteritis
Anne-Claire Desbois¹, Patrice Cacoub², Aurélie LEROYER³, Edwige Tellier⁴, Marlène Garrido⁵, Anna Maciejewski-Duval⁶, Cloé Comarmond⁷, Stéphane Barete⁶, Michel Arock⁶, Patrick Bruneval⁸, Jean-Marie Launay⁹, Pierre Fouret¹⁰, Ulrich Blank¹¹, Michelle Rosenzwajg⁶, David Klatzman¹², Mohamed Jarraya¹³, Philippe Cluzel¹⁴, Fabien Koskas¹⁵, Gilles Kaplanski¹⁶ and David Saadoun¹⁷, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ³Faculté de Pharmacie, Marseille, France, ⁴Université Marseille, Marseille, France, ⁵I3 laboratory, Pitié-Salpétrière, Paris, France, ⁶GHPS, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁸HEGP, Paris, France, ⁹Hôpital lariboisière, Paris, France, ¹⁰Hôpital La Pitié Salpétrière, Paris, France, ¹¹Hôpital Bichat, Paris, France, ¹²UPMC Université Paris 06, UMR 7211, Paris, France, ¹³Hôpital Saint Louis, Paris, France, ¹⁴Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ¹⁵Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ¹⁶Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹⁷Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France
Background/Purpose: Large vessel vasculitis (LVV) include Takayasu arteritis (TA) and giant cell arteritis (GCA). Arterial lesions in LVV result from chronic inflammation and neoangiogenesis. IL-33,…
Abstract Number: 972 • 2015 ACR/ARHP Annual Meeting
A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Ronald F. van Vollenhoven¹, Edward C. Keystone², Vibeke Strand³, Cesar Pacheco-Tena⁴, Jiri Vencovsky⁵, Frank Behrens⁶, Daniela Zipp⁷, Faiza Rharbaoui⁸, Ralf Wolter⁹, Rolf-Dietrich Tiemann¹⁰, Luise Knierim¹¹, Rainer Schmeidl¹¹, Xuefei Zhou¹², Silke Aigner^8,13, Benjamin Daelken¹⁴ and Andrea Wartenberg-Demand^8,12, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Landseinerstr 5, Biotest AG, Dreieich, Germany, ⁸Biotest AG, Dreieich, Germany, ⁹Corporate Clinical Research, L, Biotest AG, Dreieich, Germany, ¹⁰Data Management and Outsourcing, Biotest AG, Dreieich, Germany, ¹¹Cooperate Drug Safety, Biotest AG, Dreieich, Germany, ¹²Cooperate Clinical Research, Biotest AG, Dreieich, Germany, ¹³Landsteinerstrasse 5, Biotest AG, Dreieich, Germany, ¹⁴Project Managerment Office, Biotest Pharmaceuticals Corporation, Boca Raton, FL
Background/Purpose: In autoimmune diseases reduced numbers and functional impairment of regulatory T cells (Tregs) have been observed (1). Tregalizumab (BT-061) is a humanized, anti-CD4 mAb,…
Abstract Number: 2910 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura¹, Jun Saegusa¹, Fumichika Matsuki², Kengo Akashi¹, Goichi Kageyama¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are characterized by the co-expression of Gr1 and CD11b in mice. MDSCs suppress…
Abstract Number: 1456 • 2014 ACR/ARHP Annual Meeting
Foxp3+ Regulatory T Cells in Peripheral Blood and Synovial Fluid of Patients with RA: A Comparative Phenotypic Analysis
Jun Saegusa¹, Fumichika Matsuki², Yasushi Miura³, Goichi Kageyama², Seiji Kawano², Shunichi Kumagai⁴ and Akio Morinobu², ¹Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ⁴Center for Rheumatic Disease, Shinko Hospital, Kobe, Japan
Background/Purpose: Human regulatory T (Treg) cells play an indispensable role for the maintenance of self tolerance and immune homeostasis. Numerous studies dealt with Treg population…
Abstract Number: 950 • 2014 ACR/ARHP Annual Meeting
Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis
Soi-Cheng Law¹, Hendrik Nel², Ahmed Mehdi², Kim-Anh Le Cao² and Ranjeny Thomas³, ¹Diamantina Institute, Univ of Queensland, Brisbane, Australia, ²Diamantina Institute, University of Queensland, Brisbane, Australia, ³Diamantina Institute, Univ of Queensland, Brisbane, QLD, Australia
Background/Purpose We carried out a phase I clinical trial of tolerising autologous peripheral blood DCs exposed to 4 citrullinated self-peptides (“Rheumavax”) in 29 HLA-DR shared…
Abstract Number: 2505 • 2012 ACR/ARHP Annual Meeting
Involvment of CD4⁺ FoxP3⁺ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis
Allan Thiolat¹, Jerome Biton¹, Luca Semerano¹, Yves-Marie Pers², Pierre Portales², Delphine Lemeiter¹, Patrice Decker¹, Christian Jorgensen², Pascale Louis-Plence², Natacha Bessis³ and Marie-Christophe Boissier⁴, ¹EA4222, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 93009, France, Bobigny, France, ²Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ⁴INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose: Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for…
Abstract Number: 2346 • 2012 ACR/ARHP Annual Meeting
MHC II-Independent Regulation of Intestinal Tregs
Lisa L. Korn¹ and Terri M. Laufer², ¹Medicine, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Regulatory T cells (Tregs) are critical to prevent autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis. Like all CD4+ T cells, CD4+…
Abstract Number: 2325 • 2012 ACR/ARHP Annual Meeting
PD-1 Signaling Promotes Suppressive Function of CD4⁺ Regulatory T Cells in (New Zealand Black x New Zealand White )F₁ Lupus-Prone Mice in a Dose-Dependent Manner
Maida Wong¹, Antonio La Cava² and Bevra H. Hahn³, ¹Internal Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Internal Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Programmed death-1 (PD-1) has been regarded as a negative regulatory signal in T cells. Our laboratory has shown that PD-1 is important in T…
Abstract Number: 2343 • 2012 ACR/ARHP Annual Meeting
The Therapeutic Antibody Tregalizumab (BT-061) Induces Activation of Regulatory T Cells by Engaging a Unique CD4 Mediated Signaling That Strongly Differs From Signaling Events Induced by Standard Anti-CD4 Antibodies
Bianca Helling¹, Benjamin Daelken¹, Holger Wallmeier², Silke Aigner¹, Chantal Zuber¹, Martin Koenig¹, Andre Engling¹, Frank Osterroth¹, Niklas Czeloth³ and Christoph Uherek¹, ¹Biotest AG, Dreieich, Germany, ²Condor Scientific Computing & Consulting, Sulzbach, Germany, ³Global Research Immunology, Biotest AG, Dreieich, Germany
Background/Purpose: The humanized CD4 specific monoclonal antibody (mAb) tregalizumab is currently being tested in phase II clinical trials in Rheumatoid Arthritis. In contrast to other…
Abstract Number: 2075 • 2012 ACR/ARHP Annual Meeting
CCR6⁺Foxp3⁺ Regulatory T Cells Regulate the Development of Collagen Induced Arthritis in T Cell Specific RORγt Transgenic Mice
Yuya Kondo¹, Masahiro Tahara¹, Mana Iizuka¹, Hiroto Tsuboi¹, Satoru Takahashi², Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Recent studies reported that IL-17 producing Th-17 cells appear to play an important role in the generation of several autoimmune arthritis models. We previously…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].